Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of nonvalvular atrial fibrillation atrial flutter by electrocardiogram and echocardiography;~* CHA2DS2VASc score equal to or greater than 1;~* already in use of warfarin for at least 2 months;~* during the run-in, at least one of the three (including the baseline) INR results within 2.0 and 3.0 and a difference of INR results at the 3th and 4th week ≤ ±0.8~* signing of Informed Consent Form.~Exclusion Criteria:~* patients with serious contraindications to the use of anticoagulants (significant bleeding, known sensitivity to warfarin);~* women of childbearing age, pregnant or breastfeeding;~* patients with thrombocytopenia;~* patients with hepatic or renal impairment;~* patients with a history of bleeding episodes due to congenital deficiency of coagulation factors;~* patients enrolled in another trial;~* patients initiating treatment with drugs with major interactions or which are contraindicated when used concomitantly with warfarin, according to our list (Annex I).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sequence A (Type: OTHER): Phase 1 (run-in): Marevan®~Phase 2: Marevan®~Phase 3: generic warfarin #1~Phase 4: generic warfarin #2
- Sequence B (Type: OTHER): Phase 1 (run-in): generic warfarin #1~Phase 2: generic warfarin #1~Phase 3: Marevan®~Phase 4: generic warfarin #2
- Sequence C (Type: OTHER): Phase 1 (run-in): generic warfarin #1~Phase 2: generic warfarin #1~Phase 3: generic warfarin #2~Phase 4: Marevan®
- Sequence D (Type: OTHER): Phase 1 (run-in): Marevan®~Phase 2: Marevan®~Phase 3: generic warfarin #2~Phase 4: generic warfarin #1
- Sequence E (Type: OTHER): Phase 1 (run-in): generic warfarin #2~Phase 2: generic warfarin #2~Phase 3: Marevan®~Phase 4: generic warfarin #1
- Sequence F (Type: OTHER): Phase 1 (run-in): generic warfarin #2~Phase 2: generic warfarin #2~Phase 3: generic warfarin #1~Phase 4: Marevan®

Based on this trial design, predict the completion outcome and termination type (if applicable).